Zentaris teams up with Chinese company to make cancer drug
German company Zentaris, the Frankfurt-based biopharmaceutical subsidiary of AEterna Laboratories, of Canada, has signed a contract with Chinese company Hainan Tianwang International Pharmaceutical for the manufacture and marketing of Lobaplatin in China.
German company Zentaris, the Frankfurt-based biopharmaceutical subsidiary of AEterna Laboratories, of Canada, has signed a contract with Chinese company Hainan Tianwang International Pharmaceutical for the manufacture and marketing of Lobaplatin in China.
Lobaplatin, a patented platinum-based cancer drug, has already received marketing authorisation in China.
The technology transfer agreement provides for Zentaris to receive a one-off payment of C$4.5m (€2.8m). In addition, Tianwang is contracted to manu-facture and deliver Lobaplatin to Zentaris or its part-ners for marketing in all other countries worldwide. 'The collaboration with Tianwang reflects an important strategic move for Zentaris as it forms the basis for future success in the fast-growing Chinese market,' said ceo Prof. Dr Jurgen Engel.